Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination

Intern Med. 2022 Nov 15;61(22):3453-3457. doi: 10.2169/internalmedicine.0293-22. Epub 2022 Sep 6.

Abstract

Coronavirus disease 2019 (COVID-19) vaccines have been delivered worldwide to prevent the spread of the disease, and almost all Japanese have received the mRNA vaccines "BNT162b2" (Pfizer-BioNTech) or "mRNA-1273" (Moderna). These vaccines have shown efficacy and safety with only minor adverse drug reactions. However, some patients develop severe adverse drug reactions, including autoimmune reactions. In addition, systemic vasculitis, mainly small-vessel vasculitis, following COVID-19 vaccination, has been reported. However, only a few investigators have reported medium-vessel vasculitis following vaccination. We herein report a case of medium-vessel vasculitis presenting with myalgia as the initial clinical manifestation following COVID-19 Moderna vaccination.

Keywords: COVID-19; autoimmune phenomena; mRNA vaccine; medium-vessel vasculitis; myalgia.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Myalgia / etiology
  • Vaccination
  • Vaccines*
  • Vasculitis* / etiology

Substances

  • COVID-19 Vaccines
  • Vaccines